engleski

SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version

Differentiated thyroid cancers (DTC) are slow- growing tumors with very low disease-specific mortality rates for local−regional disease (5-y survival: 99.9% for localized disease, 98.3% for regional metastatic disease). However, distant metastatic disease is associated with significantly worse prognosis (5-y survival: 54.9%) (1). Standard-of-care management for DTC includes risk-adapted surgery, postoperative 131I therapy, and thyroid hormone therapy. In uncommon cases of radioiodine-refractory tumors, additional therapy may include reoperative surgical intervention, external radiotherapy, and interventional radiology for treatment of locoregional metastases and multikinase or tyrosine kinase inhibitors for treatment of distant metastatic disease.

differentiated thyroid cancer, guideline

nije evidentirano